Metropolitan Life Insurance Company (MetLife)’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-45,593	Closed	-$413K	–	2772
2013 Q4	$413K	Hold	45,593	–	–	﹤0.01%	1938
2013 Q3	$288K	Hold	45,593	–	–	﹤0.01%	2141
2013 Q2	$311K	Buy	+45,593	New	+$318K	﹤0.01%	2020

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CADX Position: Q1 2014 in Review

Metropolitan Life Insurance Company (MetLife) sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 45,593 shares — an estimated $413K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $413K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Metropolitan Life Insurance Company (MetLife) reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 45,593 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $413K.
Metropolitan Life Insurance Company (MetLife) first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Metropolitan Life Insurance Company (MetLife)'s CADENCE PHARMACEUTICALS, INC COM STK position peaked at $413K in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2014, filed 25 Apr 2014.